Mersana Therapeutics Inc [MRSN] stock is trading at $0.37, up 8.79%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MRSN shares have gain 6.13% over the last week, with a monthly amount drifted -6.53%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On March 19, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $5 on the stock. Wedbush upgraded its rating to a Outperform and increased its price target to $7 on February 29, 2024. Guggenheim upgraded its rating to a Buy but $7 remained the price target by the analyst firm on February 29, 2024. BTIG Research upgraded its rating to Buy for this stock on February 29, 2024, but kept the price target unchanged to $6. In a note dated December 04, 2023, Citigroup upgraded an Buy rating on this stock and boosted its target price from $1 to $5.
Mersana Therapeutics Inc [MRSN] stock has fluctuated between $0.26 and $2.83 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $0.37 at the most recent close of the market. An investor can expect a potential return of 710.81% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
Mersana Therapeutics Inc [NASDAQ:MRSN] reported sales of 34.01M for the trailing twelve months, which represents a drop of -70.21%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.26%, Pretax Profit Margin comes in at -2.16%, and Net Profit Margin reading is -2.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is 9.58 and Total Capital is -1.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3516 points at the first support level, and at 0.3293 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3881, and for the 2nd resistance point, it is at 0.4023.
Ratios To Look Out For
For context, Mersana Therapeutics Inc’s Current Ratio is 1.83. As well, the Quick Ratio is 1.83, while the Cash Ratio is 1.76. Considering the valuation of this stock, the price to sales ratio is 1.37.
Transactions by insiders
Recent insider trading involved Mandelia Ashish, VP, Chief Accounting Officer, that happened on Jan 16 ’25 when 3554.0 shares were sold. Director, Protopapas Anna completed a deal on Jan 16 ’25 to sell 8637.0 shares. Meanwhile, SVP, Chief Sci.&Tech. Officer Lowinger Timothy B sold 8048.0 shares on Jan 16 ’25.
